Concourse Financial Group Securities, Inc. Biotechnology

Concourse Financial Group Securities, Inc.

$0
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
PMCB Pharma Cyte Biotech, Inc.	$22.8M	$0 100.0% of portfolio	0	Q1 2025 New
PHAR Pharming Group N.V.	$731M	$0 100.0% of portfolio	0	Q1 2025 New
PHVS Pharvaris N.V.	$542M	$0 100.0% of portfolio	0	Q1 2025 New
PHAT Phathom Pharmaceuticals, Inc.	$186M	$0 100.0% of portfolio	0	Q1 2025 New
PHIO Phio Pharmaceuticals Corp.	$28.5M	$0 100.0% of portfolio	0	Q1 2025 New
PLRX Pliant Therapeutics, Inc.	$79.8M	$0 100.0% of portfolio	0	Q1 2025 New
PMVP Pmv Pharmaceuticals, Inc.	$43.3M	$0 100.0% of portfolio	0	Q1 2025 New
PGEN Precigen, Inc.	$308M	$0 100.0% of portfolio	0	Q1 2025 New
PRLD Prelude Therapeutics Inc	$36.4M	$0 100.0% of portfolio	0	Q1 2025 New
PROK Prokidney Corp Ord Shs Cl A(Cy	$44.3M	$0 100.0% of portfolio	0	Q1 2025 New
PRQR Pro Qr Therapeutics N.V.	$127M	$0 100.0% of portfolio	0	Q1 2025 New
PTIX Protagenic Therapeutics, Inc.New	$63.2M	$0 100.0% of portfolio	0	Q1 2025 New
PTGX Protagonist Therapeutics, Inc	$2.66B	$0 100.0% of portfolio	0	Q1 2025 New
PLX Protalix Bio Therapeutics, Inc.	$80.1M	$0 100.0% of portfolio	0	Q1 2025 New
TARA Protara Therapeutics, Inc.	$37M	$0 100.0% of portfolio	0	Q1 2025 New
PRTA Prothena Corp Public LTD CO	$237M	$0 100.0% of portfolio	0	Q1 2025 New
PTCT Ptc Therapeutics, Inc.	$3.7B	$0 100.0% of portfolio	0	Q1 2025 New
PBYI Puma Biotechnology, Inc.	$154M	$0 100.0% of portfolio	0	Q1 2025 New
PRTC Pure Tech Health PLC	$524M	$0 100.0% of portfolio	0	Q1 2025 New
PYXS Pyxis Oncology, Inc.	$47M	$0 100.0% of portfolio	0	Q1 2025 New
QSI Quantum Si Inc	$201M	$0 100.0% of portfolio	0	Q1 2025 New
RLYB Rallybio Corp	$11.6M	$0 100.0% of portfolio	0	Q1 2025 New
RANI Rani Therapeutics Holdings, Inc.	$13M	$0 100.0% of portfolio	0	Q1 2025 New
RAPT Rapt Therapeutics, Inc.	$30.2M	$0 100.0% of portfolio	0	Q1 2025 New
RXRX Recursion Pharmaceuticals, Inc.	$825M	$0 100.0% of portfolio	0	Q1 2025 New
REGN Regeneron Pharmaceuticals, Inc.	$51.8B	$0 100.0% of portfolio	0	Q1 2025 Sold Out
RGNX Regenxbio Inc.	$361M	$0 100.0% of portfolio	0	Q1 2025 New
RGLS Regulus Therapeutics Inc.	$119M	$0 100.0% of portfolio	0	Q1 2025 New
RLAY Relay Therapeutics, Inc.	$390M	$0 100.0% of portfolio	0	Q1 2025 New
RLMD Relmada Therapeutics, Inc.	$23.5M	$0 100.0% of portfolio	0	Q1 2025 New
RNXT Renovo Rx, Inc.	$12.4M	$0 100.0% of portfolio	0	Q1 2025 New
RPTX Repare Therapeutics Inc.	$62.5M	$0 100.0% of portfolio	0	Q1 2025 New
REPL Replimune Group, Inc.	$481M	$0 100.0% of portfolio	0	Q1 2025 New
REVB Revelation Biosciences, Inc.	$21.2M	$0 100.0% of portfolio	0	Q1 2025 New
RVPH Reviva Pharmaceuticals Holdings, Inc.	$16.8M	$0 100.0% of portfolio	0	Q1 2025 New
RVMD Revolution Medicines, Inc.	$3.53B	$0 100.0% of portfolio	0	Q1 2025 New
RZLT Rezolute, Inc.	$172M	$0 100.0% of portfolio	0	Q1 2025 New
RYTM Rhythm Pharmaceuticals, Inc.	$3.66B	$0 100.0% of portfolio	0	Q1 2025 New
RCKT Rocket Pharmaceuticals, Inc.	$210M	$0 100.0% of portfolio	0	Q1 2025 New
ROIV Roivant Sciences Ltd.	$7.89B	$0 100.0% of portfolio	0	Q1 2025 New
RPRX Royalty Pharma PLC	$14.8B	$0 100.0% of portfolio	0	Q1 2025 Sold Out
RUBY Rubius Therapeutics, Inc.	$0	$0 100.0% of portfolio	0	Q1 2025 New
SABSW Sab Biotherapeutics Inc Wt Exp	$0	$0 100.0% of portfolio	0	Q1 2025 New
SAGE Sage Therapeutics, Inc.	$403M	$0 100.0% of portfolio	0	Q1 2025 New
SANA Sana Biotechnology, Inc.	$485M	$0 100.0% of portfolio	0	Q1 2025 New
SGMO Sangamo Therapeutics, Inc	$76.7M	$0 100.0% of portfolio	0	Q1 2025 New
SRPT Sarepta Therapeutics, Inc.	$3.43B	$0 100.0% of portfolio	0	Q1 2025 Sold Out
SVRA Savara Inc	$285M	$0 100.0% of portfolio	0	Q1 2025 New
SRRK Scholar Rock Holding Corp	$1.83B	$0 100.0% of portfolio	0	Q1 2025 New
SCPH Sc Pharmaceuticals Inc.	$107M	$0 100.0% of portfolio	0	Q1 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.